Although recombinant PEDF has been evaluated as a full-length protein or a functional polypeptide fragment in preclinical models of diabetic retinopathy [13] and nAMD [14], the relatively short half-life of recombinant PEDF after intravitreal injection is a major hurdle for long-term clinical treatment. Here, SERPINF1 is linked to diabetic retinopathy.